In-vitro and in-vivo effects of Cilengitide in Glioblastoma models

Introduction: Glioblastoma multiforme still has a very poor prognosis even with today's multimodal therapy of resection followed by radio-chemotherapy with Temozolomide. Among numerous new antitumor compounds currently under investigation, the integrin inhibitor Cilengitide has reached phase II studies, e.g. the German pediatric glioblastoma relapse study CilMetro. Materials and Methods: At our institution we established a collection of primary glioblastoma cell lines and characterised their molecular patterns including integrin expression and MGMT promoter methylation. In these, in-vitro effects of Cilengitide…